非格司亭诱导的肝髓外造血导致伯基特淋巴瘤患者18F-FDG PET/CT假阳性
本文报告一例分期时以结外病变为主的伯基特淋巴瘤病例。化疗后对照PET显示原病灶均达完全代谢缓解,但肝脏出现新发局灶性摄取增高,超声与MRI证实,肝活检示髓外造血,可能由非格司亭诱导。作者指出非格司亭给药可能导致肝脏FDG PET假阳性。
要点
- 伯基特淋巴瘤化疗后PET示原病灶完全代谢缓解,但肝脏新发局灶性FDG摄取增高。
- 超声与MRI证实肝脏病灶,肝活检示髓外造血,可能由非格司亭诱导。
- 作者指出非格司亭给药可能导致肝脏FDG PET假阳性。
核心结论
- 非格司亭给药可能导致肝脏FDG PET假阳性表现。
研究设计与样本
- 本文为病例报告,报告一例分期时以结外病变为主的伯基特淋巴瘤患者。
主要发现
- 化疗后对照PET显示原所有病灶达完全代谢缓解,同时肝脏出现新发局灶性摄取增高区,超声与MRI证实这些表现。
- 化疗所致中性粒细胞减少经非格司亭治疗后出现迅速且明显的髓性反应,肝活检示髓外造血,可能为非格司亭诱导。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We report a case of Burkitt lymphoma with largely extranodal disease localizations at staging. Chemotherapy was given, thus obtaining a complete metabolic response in all previous disease sites as shown at a control PET, however associated to the appearance of new focal uptake areas in the liver; these findings were confirmed at US and MRI. Chemotherapy determined also neutropenia that was treated by filgrastim, followed by a prompt and important medullary response. Liver biopsy revealed extramedullary hematopoiesis, probably filgrastim induced. Filgrastim administration may cause false-positive findings in the liver at FDG PET.
引用
- Maffione AM, Rampin L, Rossella P, et al. False-Positive 18F-FDG PET/CT Due to Filgrastim That Induced Extramedullary Liver Hematopoiesis in a Burkitt Lymphoma. Clin Nucl Med. 2018. PMID: 29401143. doi:10.1097/RLU.0000000000001998
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。